Antisense Therapeutics Limited

ASX:ANP.AX

0.06 (AUD) • At close January 3, 2024
Bedrijfsnaam Antisense Therapeutics Limited
Symbool ANP.AX
Munteenheid AUD
Prijs 0.058
Beurswaarde 52,289,611
Dividendpercentage 0%
52-weken bereik 0.05 - 0.11
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Website https://www.antisense.com.au

An error occurred while fetching data.

Over Antisense Therapeutics Limited

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline

Vergelijkbare Aandelen

Microba Life Sciences Limited logo

Microba Life Sciences Limited

MAP.AX

0.18 AUD

Noxopharm Limited logo

Noxopharm Limited

NOX.AX

0.11 AUD

Orthocell Limited logo

Orthocell Limited

OCC.AX

0.4 AUD

Emyria Limited logo

Emyria Limited

EMD.AX

0.044 AUD

MedAdvisor Limited logo

MedAdvisor Limited

MDR.AX

0.345 AUD

Biotron Limited logo

Biotron Limited

BIT.AX

0.017 AUD

Micro-X Limited logo

Micro-X Limited

MX1.AX

0.058 AUD

Invion Limited logo

Invion Limited

IVX.AX

0.002 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)